બાઇલ ડક્ટ કેન્સર
Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients
ક્યાં જવું
ભારતમાં 3 હોસ્પિટલ આ trial માટે દર્દીઓ લઈ રહી છે.
રજિસ્ટ્રી સમરી (ટેકનિકલ)
This is a randomized, open-label, two-arm, Phase III clinical trial evaluating the efficacy and safety of trastuzumab plus chemotherapy versus chemotherapy alone as first-line treatment in patients with HER2-positive advanced or metastatic biliary tract cancers (BTC). HER2-positive BTCs represent a molecular subset of these rare cancers, associated with poor prognosis and limited treatment options. Eligible patients with histologically confirmed HER2-positive (IHC 3+ or IHC 2+ with FISH amplification) unresectable or metastatic biliary tract adenocarcinoma-including gallbladder cancer, intrah…
સ્પોન્સર: ટાટા મેમોરિયલ સેન્ટર
ClinicalTrials.gov પર NCT07062263
રજિસ્ટ્રીમાં છેલ્લે 14 Jul 2025 ના રોજ અપડેટ થયું · અમે 20 Oct 2026 ના રોજ વાંચ્યું